Your browser doesn't support javascript.
loading
Cas12a/Guide RNA-Based Platform for Rapidly and Accurately Detecting blaKPC Gene in Carbapenem-Resistant Enterobacterales.
Li, Keke; Wu, Yaozhou; Liu, Meng; Yan, Junwen; Wei, Lianhua.
Afiliación
  • Li K; Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, 730000, People's Republic of China.
  • Wu Y; Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, 730000, People's Republic of China.
  • Liu M; First School of Clinical Medicine, Lanzhou University, Lanzhou, 730000, People's Republic of China.
  • Yan J; Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, 730000, People's Republic of China.
  • Wei L; Department of Clinical Laboratory, Gansu Provincial Hospital, Lanzhou, 730000, People's Republic of China.
Infect Drug Resist ; 17: 2451-2462, 2024.
Article en En | MEDLINE | ID: mdl-38915320
ABSTRACT

Purpose:

Accurate detection and identification of pathogens and their associated resistance mechanisms are essential prerequisites for implementing precision medicine in the management of Carbapenem-resistant Enterobacterales (CRE). Among the various resistance mechanisms, the production of KPC carbapenemase is the most prevalent worldwide. Consequently, this study aims to develop a convenient and precise nucleic acid detection platform specifically for the blaKPC gene.

Methods:

The initial phase of our research methodology involved developing a CRISPR/Cas12a detection framework, which was achieved by designing highly specific single-guide RNAs (sgRNAs) targeting the blaKPC gene. To enhance the sensitivity of this system, we incorporated three distinct amplification techniques-polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA)-into the CRISPR/Cas12a framework. Subsequently, we conducted a comparative analysis of the sensitivity and specificity of these three amplification methods when used in combination with the CRISPR/Cas12a system. Additionally, we assessed the clinical applicability of the methodologies by evaluating fluorescence readouts from 80 different clinical isolates. Furthermore, we employed lateral flow assay technology to provide a visual representation of the results, facilitating point-of-care testing.

Results:

Following a comparative analysis of the sensitivity and specificity of the three methods, we identified the RPA-Cas12a approach as the optimal detection technique. Our findings demonstrated that the limit of detection (LoD) of the RPA-Cas12a platform was 1 aM (~1 copy/µL) for plasmid DNA and 5 × 10³ fg/µL for genomic DNA. Furthermore, both the sensitivity and specificity of the platform achieved 100% upon validation with 80 clinical isolates.

Conclusion:

These findings suggest that the developed RPA-Cas12a platform represents a promising tool for the cost-effective, convenient, and accurate detection of the blaKPC gene.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Infect Drug Resist Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Infect Drug Resist Año: 2024 Tipo del documento: Article